Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 6
Submit an article Journal homepage
66
Views
8
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pexelizumab – a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass

Ani J Fleisig University of Washington, Division of Cardiothoracic Surgery, 1959 NE Pacific Seattle, Washington, WA 98195, USA. [email protected]
&
Edward D Verrier University of Washington, Division of Cardiothoracic Surgery, 1959 NE Pacific Seattle, Washington, WA 98195, USA. [email protected]
Pages 833-839 | Published online: 24 Nov 2005

Bibliography

  • AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics, 2004 update. (2004).
  • NIAN M, LEE P, KHAPER N, LIU P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. (2004) 94(12):1543–1553.
  • MONSINJON T, RICHARD V, FONTAINE M: Complement and its implications in cardiac ischaemia/ reperfusion: strategies to inhibit complement. Fundam. Clin. Pharmacol. (2001) 15(5):293–306.
  • WAN S, LECLERC JL, VINCENT JL: Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest (1997) 112(3):676–692.
  • LEVY JH, TANAKA KA: Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. (2003) 75(2):5715–5720.
  • BRAUNWALD E, FAUCI AS, KASPER DL, HAUSER SL, LONGO DL, JAMESON JL: Harrison's Principles of Internal Medicine (15th edition). Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (Eds), McGraw-Hill, New York, USA (2001).
  • JOHANSSON-SYNNERGREN M, NILSSON F, BENGTSSON A. JEPPSSON A, WIKLUND L: Off-pump CABG reduces complement activation but does not significantly affect peripheral endothelial function: a prospective randomized study. Scand. Cardiovasc. (2004) 38(1):53–58.
  • VAKEVA AP, AGAH A, ROLLINS SA, MATIS LA, LI L, STAHL GL: Myocardial infarction and apoptosis after myocardial ischaemia and reperfusion: role of the terminal complement components and inhibition by anti-05 therapy. Circulation (1998) 97(22):2259–2267.
  • FITCH JC, ROLLINS S, MATIS Let al.: Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation (1999) 100(25):2499–2506.
  • MAHAFFEY KW, GRANGER CB, NICOLAU JC et al.: Effect of pexelizumab, an anti-05 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. COMPLY Investigators. Circulation (2003) 108(141176–1183.
  • GRANGER CB, MAHAFFEY KW, WEAVER WD et al.: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. COMMA Investigators. Circulation (2003) 108(10):1184–1190.
  • KONG DF, HASSELBLAD HARRINGTON RA et al.: Meta-analysis of survival with platelet glycoprotein IIb/ IIIa antagonists for percutaneous coronary interventions. Am. J. CardioL (2003) 92(6):651–655.
  • BERANEK JT: Why did the anti-05 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Circulation (2004) 109(16):e195–e196; author reply e195–e196.
  • SHERNAN SK, FITCH JC, NUSSMEIER NA et al.: Impact of pexelizumab, an anti-05 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Pexelizumab Study Investigators. Ann. Thorac. Surg. (2004) 77(3):942–949; discussion 949–950.
  • MATHEW JP, SHERNAN SK, WHITE WD et al.: Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke (2004) 35(10):2335–2339.
  • VERRIER ED, SHERNAN SK, TAYLOR KM et al.: Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. PRIMO-CABG Investigators. JAMA (2004) 291(19):2319–2327.

Websites

  • http://www.who.int World Health Report 2003 — shaping the world, WHO 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.